Completed PHASE2 INTERVENTIONAL 2-arm NCT03237312

Serum Anti-mullerian Hormone and Polycystic Ovarian Syndrome

The Impact of Serum Antimullerian Hormone Level on Adjusting the Number of Ovarian Drills in Polycystic Ovarian Syndrome

Sponsor: Assiut University

Conditions Polycystic Ovary Syndrome

Interventions Antimullerian hormone Laparoscopic ovarian drilling

Updated 5 times since 2017 Last updated: Jul 30, 2017 Started: Jan 1, 2015 Primary completion: Sep 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Polycystic Ovary Syndrome and is currently completed. Assiut University leads this study, which shows 5 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assiut University

Data source: Assiut University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Asyut, Egypt